| Insider | Role | Shares | Value | Buys | Sells |
|---|---|---|---|---|---|
| Date | Ticker | Insider | Role | Type | Shares | Price | Value | Chg% | SEC |
|---|---|---|---|---|---|---|---|---|---|
| Insider | Role | Shares | Value | Buys | Sells |
|---|---|---|---|---|---|
| Date | Ticker | Insider | Role | Type | Shares | Price | Value | Chg% | SEC |
|---|---|---|---|---|---|---|---|---|---|
Crinetics Pharmaceuticals, Inc. (CRNX) has 7 insiders with recent SEC Form 4 filings, including 0 buys and 11 sells. CRNX is classified in the Biotechnology industry within the Health Care sector.
| Role | Insider | Shares | Value | 30d |
|---|---|---|---|---|
| COO | 121.9K | $4.34M | - | |
| CEO | 111.1K | $3.95M | - | |
| CFO | 84.8K | $3.02M | - | |
| Other | 69.0K | $2.46M | - | |
| Other | 47.0K | $1.67M | - |
Buys and sells only
| Date | Insider | Role | Type | Shares | Price | Value | Chg% | 3M | 12M | SEC |
|---|---|---|---|---|---|---|---|---|---|---|
| Jan 5, 2026 | Kalofonos Isabel | Chief Commercial Officer | Sale+OE | 2,500 | $55.00 | $137,500.00 | -75.0% | -21.8% | - | |
| Dec 1, 2025 | Pizzuti Dana56 | Chief Med And Dev Officer | Sale+OE | 5,000 | $45.02 | $225,100.00 | -7.0% | -10.0% | - | |
| Nov 3, 2025 | Pizzuti Dana56 | Chief Med And Dev Officer | Sale+OE | 5,000 | $42.66 | $213,312.00 | -3.6% | +15.2% | - | |
| Oct 1, 2025 | Pizzuti Dana56 | Chief Med And Dev Officer | Sale+OE | 5,000 | $41.81 | $209,050.00 | -7.0% | +13.9% | - | |
| Sep 26, 2025 | Struthers Richard Scott54 | President &CEO | Sell | 4,000 | $45.00 | $180,000.00 | -3.6% | +4.5% | - | |
| Sep 26, 2025 | Fust Matthew K77 | Director | Sale+OE | 16,000 | $44.75 | $716,000.00 | -41.2% | +4.5% | - | |
| Sep 2, 2025 | Pizzuti Dana56 | Chief Med And Dev Officer | Sale+OE | 5,000 | $32.10 | $160,500.00 | -4.9% | +35.9% | - | |
| Aug 22, 2025 | Pizzuti Dana56 | Chief Med And Dev Officer | Sale+OE | 30,000 | $30.43 | $912,900.00 | -31.2% | +35.7% | - | |
| Aug 20, 2025 | Pizzuti Dana56 | Chief Med And Dev Officer | Sell | 6,492 | $29.18 | $189,436.56 | -8.9% | +47.9% | - | |
| Jun 12, 2025 | Betz Stephen F.61 | Chief Scientific Officer | Sale+OE | 97,483 | $32.23 | $3,141,877.09 | -49.4% | +8.8% | +7.1% |